Latin America Vagus Nerve Stimulation Market Report: Market Size & Forecast 2026

Vagus Nerve Stimulation is an established neuromodulation therapy that delivers controlled electrical pulses to the vagus nerve, either through an implanted device or non-invasive external approaches. In Latin America, VNS has traditionally served patients with drug-resistant epilepsy, though its use for depression and emerging applications is expanding. The regional market remains in an early stage of adoption compared to North America and Europe, but is gradually gaining traction as healthcare systems improve.

• •Implantable VNS devices represent the dominant product segment, though non-invasive VNS is gaining attention as a complementary option
• •The market addresses a significant unmet need for patients with treatment-resistant neurological conditions who have limited alternative therapies
• •Healthcare infrastructure improvements across major Latin American markets are facilitating broader device adoption and clinical adoption

The rising burden of neurological disorders, particularly epilepsy, across Latin America is a primary catalyst for VNS market expansion. Improved diagnostic capabilities and greater physician awareness of neuromodulation therapies are driving referrals for VNS treatment. Additionally, gradual improvements in healthcare reimbursement policies and the entry of newer, less expensive device options are making VNS more accessible to patients across socioeconomic segments.

• •Increasing prevalence of epilepsy and neurological disorders in the region's growing and aging population creates a larger addressable patient pool
• •Expanding clinical evidence supporting VNS effectiveness for both epilepsy and depression indications is strengthening physician confidence
• •Government and private sector initiatives to improve neurological care access in emerging markets are supporting market development

Brazil, Mexico, and Argentina collectively represent the largest share of the Latin America VNS market, driven by their relatively advanced healthcare infrastructure and higher per-capita healthcare spending. The implantable VNS segment dominates current market share, while non-invasive VNS represents a smaller but fastest-growing category. By application, epilepsy treatment accounts for the majority of procedures, with depression treatment representing a smaller but strategically important expanding segment.

• •Brazil leads the regional market with the largest installed base of VNS procedures and relatively established reimbursement pathways
• •Mexico and Colombia are emerging as growth markets due to expanding private healthcare coverage and rising neurosurgical capabilities
• •Rural and lower-income populations remain underserved due to high device costs and limited access to specialized epilepsy centers

What are the recent trends and outlook?

The Latin America VNS market is expected to maintain its double-digit growth trajectory through the decade, supported by ongoing clinical research and expanding indications for VNS therapy. Technological advancements, including MRI-conditional devices and improved battery longevity, are making VNS more attractive to both physicians and patients considering long-term implantable therapy. As healthcare systems across the region continue to mature, VNS is likely to transition from a niche treatment available only in select centers to a more mainstream option for refractory neurological conditions.

• •MRI-conditional and next-generation implantable devices with improved safety profiles are expected to drive higher adoption rates in the coming years
• •Research into new applications, such as VNS for heart failure and chronic inflammatory conditions, may expand the total addressable market beyond traditional neurological indications
• •Healthcare policy reforms in key markets like Brazil and Mexico could improve formal reimbursement pathways and significantly boost patient access to VNS therapy